Literature DB >> 28216406

The relationship between maternal corticosteroid use and orofacial clefts-a meta-analysis.

Wen-Lin Xiao1, Xiao-Ya Liu2, Yan-Shan Liu2, Dai-Zun Zhang2, Ling-Fa Xue2.   

Abstract

The aim was to evaluate the relationship between maternal corticosteroid use during first trimester of pregnancy and risk of orofacial clefts (OC). The overall findings showed a certain association between maternal corticosteroid use and occurrence of OC, compared with non-users (OR=1.16 [95% CI: 1.01-1.33]). When study type was considered this association was significant only for case-control studies (OR=1.22 [95% CI: 1.02-1.47]), and not for cohort studies (OR=1.09 [95% CI: 0.88-1.34]) when there are many confounders (dose, route of application, disease etc.) and biases (re-call, loss-to follow-up etc.) that still need to be considered. A subgroup analysis based on the type of OC gave an overall OR of 1.41 (95% CI: 1.14-1.74) in the case-control studies for cleft lip with or without palate (CL/P) and 1.09 (95% CI: 0.80-1.48) for cleft palate only (CPO), when comparing maternal corticosteroid users with non-users. However, for cohort studies, the overall OR for CL/P is 1.06 (95% CI: 0.82-1.37) and 1.20 (95% CI: 0.83-1.75) for CPO. The absolute risk of facial cleft after prenatal exposure to corticosteroids, if any, is small.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Corticosteroids; Meta-analysis; Orofacial clefts

Mesh:

Substances:

Year:  2017        PMID: 28216406     DOI: 10.1016/j.reprotox.2017.02.006

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  6 in total

Review 1.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

Review 2.  Insights into the treatment of inflammatory bowel disease in pregnancy.

Authors:  Sarah E Shannahan; Jonathan M Erlich; Mark A Peppercorn
Journal:  Therap Adv Gastroenterol       Date:  2019-05-27       Impact factor: 4.409

3.  Autoimmune bullous diseases during pregnancy: Solving common and uncommon issues.

Authors:  Aikaterini Patsatsi; Branka Marinovic; Dedee Murrell
Journal:  Int J Womens Dermatol       Date:  2019-01-24

4.  Multi‑organ assessment via a 9.4‑Tesla MRS evaluation of metabolites during the embryonic development of cleft palate induced by dexamethasone.

Authors:  Yue Xing; Wancong Zhang; Hanxing Zhao; Zhiwei Shen; Weijie Liang; Jianda Zhou; Lungang Shi; Jiasheng Chen; Xiaoping Zhong; Shijie Tang
Journal:  Mol Med Rep       Date:  2019-08-06       Impact factor: 2.952

5.  Asthma Medication Use and Risk of Birth Defects: National Birth Defects Prevention Study, 1997-2011.

Authors:  Meredith M Howley; Eleni A Papadopoulos; Carla M Van Bennekom; Alissa R Van Zutphen; Suzan L Carmichael; JeanPierre W Munsie; Michele L Herdt; Marilyn L Browne
Journal:  J Allergy Clin Immunol Pract       Date:  2020-07-31

6.  Maternal exposure to hydroxychloroquine and birth defects.

Authors:  Meredith M Howley; Martha M Werler; Sarah C Fisher; Alissa R Van Zutphen; Suzan L Carmichael; Cheryl S Broussard; Dominique Heinke; Elizabeth C Ailes; Shannon M Pruitt; Jennita Reefhuis; Allen A Mitchell; Marilyn L Browne
Journal:  Birth Defects Res       Date:  2021-07-23       Impact factor: 2.661

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.